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Abstract
Heat shock treatment induces expression of several heat
shock proteins and subsequent post-ischemic myocardial
protection. Correlations exist between the degree of stress
used to induce the heat shock proteins, the amount of the
inducible heat shock protein 70 (HSP70) and the level of
myocardial protection. The inducible HSP70 has also been
shown to be protective in transfected myogenic cells. Here
we examined the role of human inducible HSP70 in
transgenic mouse hearts. Overexpression of the human
HSP70 does not appear to affect normal protein synthesis
or the stress response in transgenic mice compared with
nontransgenic mice. After 30 min of ischemia, upon reperfu-
sion, transgenic hearts versus nontransgenic hearts showed
significantly improved recovery of contractile force
(0.35+0.08 versus 0.16+0.05 g, respectively, P < 0.05), rate
of contraction, and rate of relaxation. Creatine kinase, an
indicator of cellular injury, was released at a high level
(67.7+23.0 U/ml) upon reperfusion from nontransgenic
hearts, but not transgenic hearts (1.6±0.8 U/ml). We con-
clude that high level constitutive expression of the human
inducible HSP70 plays a direct role in the protection of the
myocardium from ischemia and reperfusion injury. (J. Clin.
Invest. 1995.95:1854-1860.) Key words: heat shock protein-
physiology * ischemia * myocardium-pathology * transgenic
animal * hypoxia.
Introduction
It seems we are on the threshold of an era of molecular and
genetic therapeutics (1-3). Transgenic mice expressing high
levels of specific gene products have increased resistance to
cerebral ischemia (4, 5) or have enhanced myocardial function
(6). In fact, heat shock-induced changes in gene expression
have been associated with cellular protection and improved
This work was presented in part at the 1994 meeting on Biology of
Heat Shock Proteins & Molecular Chaperones at Cold Spring Harbor
and at the 67th Scientific Session of the American Heart Association.
Address correspondence to D. R. William Currie, Department of
Anatomy and Neurobiology, Dalhousie University, Halifax, Nova Sco-
tia, Canada B3H 4H7. Phone: 902-494-3343; FAX: 902-494-8008; e-
mail, R.William.Currie@dal.ca.
Received for publication 12 October 1994 and in revised form 2
December 1994.
function for more than a decade (7-9). More recently, in iso-
lated and perfused heart studies, heat shock treatment and ex-
pression of heat shock proteins were associated with improved
post-ischemic myocardial contractile recovery (10-12). In in
vivo experiments, myocardial infarct size was significantly re-
duced in heat shock-treated animals (13-15). Indeed, a direct
correlation has now been shown between the amount of the
highly inducible member of the heat shock protein 70 (HSP70)'
family of stress-induced proteins and the degree of myocardial
protection, as measured by reduction in infarct size (16).
Although heat shock treatment is associated with myocardial
protection, it is difficult to know whether the protection is due
to the overexpression of one or several proteins, or to some other
unrelated adaptive process. Overexpression of HSP70 alone was
demonstrated to protect cells from thermal injury and increase
cell survival (17, 18). We decided therefore to use transgenic
mice engineered to express constitutively high levels of human
inducible HSP70, to investigate the contribution of this protein
to myocardial protection.
Methods
Transgenic mice. Mice were cared for in accordance with the Guide to
the Care and Use of Experimental Animals of the Canadian Council on
Animal Care.
Preparation of the DNA fragments for microinjection. The Apr-
HS70 expression vector was constructed as described previously (17).
It contains the human inducible hsp70 gene under the regulation of the
,/-actin promoter. A 6.6-kb EcoRI-Hind III fragment containing the
human 63-actin promoter, IVS1 (intervening sequence 1 of the P-actin
gene), and the human hsp70 gene was made devoid of vector sequences
by preparative electrophoresis, Geneclean purification (RI0101, UK),
and passage through an Elutip-D column (Schleicher & Schuell, Ger-
many). Fragments for microinjection were dissolved in 10 mM Tris-
HCl, pH 7.6, 0.1 mM EDTA to a final concentration of 2-4 ,ug/ml.
Generation of transgenic mice. Original inbred CBA, C57B 1 /6, and
outbred NMRI mice were obtained from IFFA-CREDO (France) and
maintained in the Hellenic Pasteur Institute's facilities. CBA x C57B 1 /
6 hybrid mice (Fl) were used for the backcrossings throughout the
study. NMRI vasectomized males were used to prepare pseudopregnant
Fl females for oviduct transfers. To obtain fertilized F2 zygotes for
microinjection, 3-4-week-old F1 females were superovulated as de-
scribed (19) and mated with F1 males. Microinjection was performed
essentially as described elsewhere (20, 21). Viable eggs were trans-
ferred into oviducts of pseudopregnant females and allowed to develop
to term.
To identify transgenic founder mice, DNA was isolated from tail
biopsies at 10-15 d of age (19), digested with BglII, and analyzed
by Southern blot (22) using the microinjected fragment as a probe.
Approximate copy numbers were estimated by comparison of signal
1. Abbreviations used in this paper: HSF, heat shock transcription fac-
tor; HSP70, inducible 70-kD heat shock protein.
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intensity with that of an endogenous Thy- I single-copy gene. Transgenic
progeny from founder mice were identified by either Southern or slot-
blot hybridization analysis.
RNA analysis. Total RNA was prepared form animal tissues by
guanidinium thiocyanate extraction as described (23). S1 nuclease map-
ping was performed using as a probe a 692-bp SalI-BglII fragment,
derived from the PAT-HS70 plasmid (24). This fragment contained
277 bp of vector sequences, 63 bp of the human hsp70 gene 5' untrans-
lated region, and 352 bp of the human hsp70 gene 5' coding sequences.
The probe was 5' end labeled using [y 32p] ATP and T4 polynucleotide
kinase, purified though a G-50 spin column, denatured by boiling, and
allowed to hybridize with 30 Msg of RNA at 50'C overnight. S1 nuclease
digestion was performed at 370C for 1 h with an enzyme concentration
of 600 U/ml. Under these conditions, only the fully homologous frag-
ments were protected; these were subsequently analyzed under denatur-
ing conditions on 5% sequencing gels (25).
Protein analysis. Hearts, livers, and kidneys from four transgenic
and four nontransgenic mice were analyzed by one- and two-dimen-
sional gel electrophoresis. Hyperthermic treatment (42TC rectal tempera-
ture for 15 min) was applied to two transgenic and two nontransgenic
mice. The hyperthermia-treated mice were allowed to recover for 30
min before injection of radiolabel. Hyperthermia-treated and control
mice were given an intraperitoneal injection of 0.25 mCi of L- [35S]-
methionine (Dupont-NEN, Boston, MA; sp act > 1,000 Ci/mmol) and
overdosed with sodium pentobarbital 2 h later, and organs were excised.
Mice receiving hyperthermic treatment were injected with radioactive
label 30 min after the end of the heat shock.
One-dimensional gels. Proteins (40 sg protein per lane) were sepa-
rated by 7.5% SDS-PAGE. Gels were stained with Coomassie brilliant
blue R, destained, and photographed. Gels were then processed for
fluorography and exposed to X-Omat AR film (Eastman Kodak Co.,
Rochester, NY).
Two-dimensional gels and Western blot analysis. Protein samples
from heart ventricular muscle were analyzed by two-dimensional SDS-
PAGE (26) as previously described (27). For Western blotting, proteins
were transferred to Immobilon-P membranes (Millipore Corp., Toronto,
Ontario) at 200 mA overnight, according to the method of Towbin et
al. (28). Blots were incubated in PBS containing 5% skim milk powder
to block nonspecific binding sites on the membranes (29). Blots were
immunoreacted first with a 1:7,500 dilution of a rabbit (#799) anti-
human inducible 70-kD polyclonal antibody graciously provided by Dr.
R. M. Tanguay (Universite Laval, Quebec). Second, blots were incu-
bated in a 1:500 dilution of a peroxidase-conjugated goat anti-mouse
IgG. 4-Chloro- 1 -naphthol was used as the substrate for the visualization
of the reaction product. Blots were counterstained with amido black to
show other proteins.
Langendorifperfusion protocol. Adult mice (25-35 g) were anes-
thetized with sodium pentobarbital (50 mg/kg body wt intraperitone-
ally). Hearts were excised rapidly and immersed to ice-cold buffer,
and the aorta was cannulated on a Langendorff apparatus. Hearts were
retrogradely perfused with Krebs-Henseleit buffer consisting of 120mM
NaCl, 20 mM NaHCO3, 4.63 mM KCl, 1.17 mM KH2PO4, 1.2 mM
MgCl2, 1.25 mM CaCl2, and 8 mM glucose, pH 7.4, at a flow of 3 ml/
min for 30 min. The perfusion system was regulated during the pre-
ischemic, ischemic, and reperfusion periods at 37°C, using a water-
jacketed chamber and coil. Hearts were made ischemic by turning off
the buffer flow for 30 min and then reperfused with 3 ml/min buffer
for 30 min. Hearts were paced at 390 beats per min (6.7 Hz, 3.3 V, 3
ms) with a stimulator (model S44, Grass Instruments, Quincy, MA).
Mechanical activity was measured throughout each perfusion experi-
ment according to previously described methods (10, 11). Briefly, api-
cobasal displacement was obtained by attaching a strain gauge trans-
ducer (model FT.03, Grass Instruments) to the heart apex. The trans-
ducer was positioned to yield an initial resting tension of 0.3 g. Perfusion
pressure was measured using a pressure transducer (model P23 ID,
Gould Inc., Cleveland OH). Recordings of mechanical activity and
pressure were recorded on a polygraph (model 7, Grass Instruments).
Creatine kinase analysis. Creatine kinase release from hearts was
measured in the effluent buffer. Samples were collected during the last
minute of pre-ischemic perfusion and at 1, 5, 10, 20, and 30 min of
reperfusion. Creatine kinase content was determined by the spectropho-
tometric method of Rosalki (30) using creatine kinase kits from Sigma
Chemical Co. (St. Louis, MO).
Catalase assay. Catalase activity was determined in hearts using a
modification of previously described methods (31, 32). Briefly, 100 mg
of heart was homogenized in 0.5 ml of ice-cold Tris sucrose buffer
containing 0.25 M sucrose, 10 mM Tris-HCl, 1 mM EDTA, 0.5 mM
DTT, and 0.1 mM PMSF, pH 7.5. Samples were centrifuged at 3,000
g for 15 min, and the supernatants were recovered. Protein concentration
of the supernatants was determined by the method of Lowry et al. (33).
Samples of heart supernatants (40 I.g of protein) were brought to 1-ml
volume with an assay buffer of 35 mM phosphate buffer, pH 7.2, 0.02%
Triton X-100. The enzymatic reaction was started by adding 30 p1 of
1% H202 to the assay mixture. Catalase activity was estimated by mea-
suring the rate of H202 consumption at 240 nm in a spectrophotometer
(model DU 50, Beckman Instr., Fullerton, CA). Optical density was
recorded at 15, 25, 35, 45, and 55 s, and the velocity of the reaction
(slope) was determined.
Statistical analysis. All values expressed are mean±SEM. Differ-
ences were determined by comparison of the calculated test statistic
with the two-tailed significance limits of Student's distribution.
Results
Transgene expression. Four transgenic mouse lines (namely
2906, 2633, 2702, and 2710) were obtained as determined by
Southern blot hybridization analysis of DNA from tail biopsies
(data not shown). Expression of the transgene was monitored
using an S 1 nuclease mapping assay. To distinguish expression
of the transgene from that of the endogenous mouse hsp70,
we took advantage of a divergence in the sequences of the 5'
untranslated region in these two genes and used a 692-bp probe
containing human HSP70 coding sequences plus 63 bp of the
human 5' untranslated region. Under stringent conditions of S 1
digestion, different length fragments of this probe were pro-
tected with mouse and human hsp70 mRNAs. Using this assay,
hsp70 mRNA levels in the four transgenic mouse lines were
tested in heart tissues (Fig. 1). We found that the 2906
transgenic line expressed large amounts ofhuman hsp70 mRNA
at normal temperature, compared with the barely detectable
levels of the endogenous mouse hsp70 mRNA. We estimated
the copy number of the transgene to be - 50. Offspring of
founder mouse 2906 were selected by Southern blot or slot-
blot hybridization for transgene expression. Nontransgenic lit-
termates as well as normal mice of the same strain were used
as controls.
Protein analysis. One-dimensional gels stained with Coo-
massie brilliant blue R and fluorograms of livers and kidneys
of transgenic and nontransgenic mice and of heat-shocked
transgenic and nontransgenic mice are presented in Fig. 2. Com-
parison of liver or kidney from nontransgenic (Fig. 2 A) and
transgenic (Fig. 2 B) mice revealed no apparent difference in
the steady-state level of proteins separated by one-dimensional
gel electrophoresis. After hyperthermic treatment (lanes 2 and
4), there appears to be a similar increased accumulation of
several protein bands in the livers and kidneys of nontransgenic
and transgenic mice (compare Fig. 2A with B). De novo protein
synthesis was assessed by L- [35S]methionine radiolabeling of
heat-shocked and non-heat-shocked transgenic and non-
transgenic mice. L- ["5S]methionine incorporation was similar
for livers and kidneys of transgenic and nontransgenic mice
(data not shown). Fluorography revealed no apparent difference
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Figure 1. Specific ex-
pression of the hsp70
transgene in heart tis-
sues. Total RNA from
heart tissues was pre-
* pared from control (Fl)
and transgenic (2906,
2633, 2702, 2710) ani-
mals and subjected to SI
nuclease protection anal-
ysis. Positions of hsp70
( 4) and (3-actin (*)
probes are indicated. The
protected exogenous hu-
man hsp7O (hHS70) and
endogenous mouse
hsp70 (mHS70) tran-
scripts are shown by
arrows. A ladder of end-
labeled HaeIl digest of
pBR322 was used for
-mnAcTIN size estimation, and ,/-
actin levels were used as
an internal assay control.
in protein synthesis between the nontransgenic (Fig. 2 C) and
transgenic (Fig. 2 D) mice. Both nontransgenic and transgenic
mice appeared to respond in a similar fashion to the hyperther-
mic treatment (lanes 2 and 4). Several protein bands have
increased incorporation of L-[35S]methionine in liver and kid-
ney (compare Fig. 2 C with D).
L- [35S ] methionine-labeled proteins from hearts were sepa-
rated by two-dimensional gel electrophoresis and processed to
reveal the proteins synthesized during the 2-h labeling period.
Fluorograms of L-[355]methionine-labeled proteins revealed
no detectable basal level of synthesis of either mouse inducible
HSP70 or human HSP70 (transgene product) in the non-
transgenic or transgenic mouse hearts (Fig. 3, A and B). After
the hyperthermic treatment, mouse inducible HSP70 was easily
detectable in the nontransgenic mouse hearts (Fig. 3 C). In the
transgenic mouse hearts there was also an increase in mouse
inducible HSP70, whereas there was little or no increase in
human hsp70 gene product (Fig. 3 D; compare with Fig. 4 D).
Western analysis of two-dimensional gels of normal and
hyperthermia-treated nontransgenic and transgenic hearts is pre-
sented in Fig. 4. A small amount of mouse inducible HSP70
was detectable in the nonstressed nontransgenic mouse hearts
(Fig. 4, A and A'). After hyperthermic treatment, the accumula-
tion of mouse inducible HSP70 was visibly increased (Fig. 4,
B and B') in nontransgenic mouse hearts. Interestingly, from
the nonstressed transgenic mouse hearts, mouse inducible
HSP70 and human HSP70 fractionated into discrete spots (Fig.
2- 3 4
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Figure 2. SDS-polyacrylamide gels of L- [35S] methionine pulse-labeled
livers and kidneys. Nontransgenic and transgenic mice with and without
heat shock treatment were given an intraperitoneal injection of 0.25
mCi of L- [35S] methionine and were killed 2 h later. Mice receiving
hyperthermic treatment (lanes 2 and 4) were injected with radioactive
label 30 min after the end of the 15-min heat shock. Labeled proteins
(40 Mg protein per lane) from liver (lanes I and 2) and kidney (lanes
3 and 4) were separated by SDS-PAGE. Coomassie brilliant blue R-
stained gels (A and B) were exposed to autoradiography film (C and
D). (A and C) Nontransgenic mouse; (B and D) transgenic mouse. The
top arrow points to the 90-kD heat shock protein, and the bottom arrow
points to HSP70.
4, C and C'). A small accumulation of mouse inducible HSP70
was detectable adjacent to a larger accumulation of human
HSP70. After hyperthermic treatment, in the transgenic mouse
hearts, the accumulation of mouse inducible HSP70 was visibly
increased, whereas there was no discernible change in the
amount of human hsp70 transgene product (Fig. 4, D and D').
Contractility. Contractile data for isolated hearts from both
groups of animals is illustrated in Fig. 5. None of the parameters
differed during the equilibration period (t = 0-30 min). The
resting tension was adjusted to 0.3 g during and at the end of the
equilibration period. Ischernia produced a complete reduction in
contractility within 15 min (t = 45 min), with a progressive
increase in resting tension. The responses during ischemia did
not differ significantly between the nontransgenic and
transgenic hearts, although the rate of relaxation and the rate
of contraction appeared to decrease more slowly in transgenic
hearts. However, substantial differences in contractile recovery


































Figure 3. SDS-polyacrylamide gels of L- [35S ] methionine pulse-labeled
hearts. Proteins were labeled as described in Fig. 2. Two-dimensional
gel electrophoresis-separated radiolabeled proteins (1 mg) extracted
from hearts of control nontransgenic (A), control transgenic (B), heat
shocked nontransgenic (C), and heat-shocked transgenic (D) mice. The
arrow in each panel points to mouse HSP70.
were evident after restoration of the normal flow. After 30 min
of reperfusion (t = 90 min), hearts of transgenic animals had
significantly increased recovery of force (0.35±0.08 versus
0.16±0.05 g), rate of contraction (+dF/dt; 90.91±9.98 ver-
sus 47.08±13.99 g/s), and rate of relaxation (-dF/dt;
94.09±10.34 versus 52.33±13.04 g/s) when compared with
nontransgenic hearts. Relative to pre-ischemic values, the recov-
ery of force was 70 versus 29%, +dF/dt was 87 versus 48%,
and -dF/dt was 83 versus 50% for the transgenic versus control
hearts. In addition, the differences tended to increase according
to the reperfusion time. Resting tension changed in a similar
fashion for both groups.
Creatine kinase release. Creatine kinase release during the
pre-ischemic perfusion was undetectable in hearts from
transgenic and nontransgenic mice. Upon reperfusion, a high
level of creatine kinase was released from nontransgenic hearts
(67.7±23.0 U/ml) as compared with transgenic hearts (1.6±0.8
U/ml) (Fig. 6). At 5 min of reflow, the level of creatine kinase
was considerably reduced in nontransgenic hearts and was simi-
lar to that in transgenic hearts (13.7±8.8 versus 19.9±10.1 U/
ml, respectively).
Catalase activity. Catalase activity was not significantly dif-
ferent in the transgenic and nontransgenic hearts (1.75±6.46
[4] versus 0.83±4.84 [6] U per mg of protein; mean ±1 SD
[n]; P = NS, respectively).
Perfusion pressure. Fig. 7 illustrates pressure data from
transgenic and nontransgenic mouse hearts. Before ischemia,
no significant difference was noted between the two groups,
although nontransgenic hearts appeared to have a higher perfu-
sion pressure (107±12 mmHg) than transgenic hearts (73±14
mmlHg) (t = 30 min). Upon reperfusion (t = 60 min), perfu-
sion pressure appeared to be higher for nontransgenic hearts
than transgenic hearts, and the two experimental groups (non-
transgenic versus transgenic hearts) differed significantly
D \ ,r
Figure 4. Western Blot analysis of 70-kD heat shock proteins in mouse
hearts. Two-dimensional gel electrophoresis-separated proteins (1 mg)
extracted from hearts of control nontransgenic (A), heat-shocked non-
transgenic (B), control transgenic (C), and heat-shocked (D) mice.
After the proteins were transferred to the membrane, the membrane was
immunoreacted with a rabbit polyclonal anti-human inducible 70-kD
heat shock protein antibody. The secondary antibody was a peroxidase-
conjugated goat anti-rabbit IgG. 4-Chloro-l-naphtol was used as the
substrate for the immunoreaction (right). Blots were counterstained
with amido black (left) to show other proteins. The arrows indicate
mouse HSP70 (left) and human HSP70 (right).
(109±12 versus 69±11 mmHg; respectively) after 10 min of
reflow (t = 70 min).
Discussion
Persistent overexpression of the human hsp7O gene product in
mice does not result in observable changes in basal protein
content or synthesis. After hyperthermic treatment, the
transgenic mouse liver, kidney, and heart have a similar increase
in synthesis of a small number of proteins as the nontransgenic
mouse tissues. However, overexpression of the human hsp7O
gene product conveys a significant protection to isolated hearts
after ischemic injury, during reperfusion. The transgenic hearts
had significantly improved post-ischemic contractile recovery
and significantly lower release of creatine kinase.
In previous studies, elevated levels of the highly inducible
member of the HSP70 family of stress-induced proteins has
been associated with improved post-ischemic recovery (10-
12) and with reduction in infarct size in hearts (13-15). As
mentioned earlier, there appears to be a direct correlation be-
tween the amount of the inducible HSP70 and the amount of
myocardial protection (16). With transgenic mice overex-
pressing inducible human HSP70, assessment of the contribu-
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-Figure 5. Contractile data of isolated non-
Time (min) transgenic and transgenic hearts during perfu-
sion. Hearts from nontransgenic (open circles)
and transgenic (closed circles) mice were retro-
* * gradely perfused with Krebs-Henseleit buffer at
370(. Hearts were made ischemic by turning off
the buffer flow for 30 min (horizontal bar) and
then reperfused for 30 min. Apicobasal displace-
ment was measured by a gauge transducer
attached to the heart apex and positioned to yield
an initial resting tension of 0.3 g. (A) Contractile
force, (B) resting tension, (C) +dFldt, and (D)
,,, , , , -dFldt. Each point represents the mean±SEM
15 30 45 60 75 90 of at least II animals. *P < 0.05 from non-
transgenic values using Student's t test for un-lime (miii) paired data.
tion of inducible HSP70 to cellular protection could be exam-
ined.
Overexpression of a single protein may induce drastic
changes in cell morphology, physiology, and cell and animal
survival (34, 35). However, in the case of the mice studied
here, there was no obvious developmental or morphological
differences between nontransgenic and. transgenic mice. At the
biochemical level, protein analysis revealed no clear differences
in protein profiles of tissues from nontransgenic and transgenic
mice. Even after heat shock treatment, the transgenic tissues
respond in a similar fashion as the nontransgenics, with the
increased synthesis of several heat shock proteins (Figs. 2 and
3). Comparison of the two-dimensional gel fluorograms (Fig.
3) and the Western blots (Fig. 4) revealed that after heat shock
treatment, the human transgene is not induced whereas the en-
dogenous mouse gene is induced. It should also be noted that
a small amount of mouse inducible HSP70 is present in the
non-heat-shocked nontransgenic and transgenic mouse hearts.
The primary antibody used for the Western analysis is extremely
E Figure 6. Creatine kinase
release in effluent buffer
c 120 - * of isolated hearts during
100 - perfusion. Creatine ki-
§80 - release
60 - sured at the last minute
1° 40 of the pre-ischemic pe-
, 20 n-o I n riod and during the reper-
IIi0-fusion of hearts from
' ' nontransgenic (open cir-
15 30 45 60 76 90 cles) and transgenic
Time (nfun) (closed circles) mice.
Each point represents the
mean±SEM of at least 11 animals. *P < 0.05 from control values
using Student's t test for unpaired data.
sensitive and detects very small accumulations of the protein.
Although mouse inducible HSP70 is detectable by Western
analysis, its synthesis, as revealed by fluorography, is below a
clearly detectable level in the non-heat-shocked hearts. At the
protein level, it seems that transgenic and nontransgenic mice
do not differ except for the presence of human HSP70.
HSP70 has been reported to autoregulate its own expression
in a negative feedback loop (36). hsp7O transcription depends
on the availability of heat shock transcription factor (HSF).
HSP70 binds to HSF, thereby maintaining HSF in an inactive
form. In our transgenic model, however, high levels of human
HSP70 did not alter mouse HSP70 constitutive expression in
hearts (Figs. 3 and 4). Moreover, synthesis of mouse inducible
HSP70 after heat shock appeared in transgenic and non-
transgenic mice. It may be that human HSP70 was not able to
bind mouse HSF and regulate mouse hsp7O transcription. In-
deed, mouse HSP70 and human HSP70 are not identical. These
proteins can be resolved into discrete spots by two-dimensional
gel electrophoresis.
The contractile data revealed no significant difference dur-
140- * ** * Figure 7. Perfusion pres-
120 H I sure from isolated hearts





20 - transgenic (closed cir-
0 cles) mice were sub-
| | jected to ischemia for 30
15 30 45 60 75 90 min (horizontal bar).
Time (min) Hearts were perfused at a
fixed flow of 3.0 ml/min
during pre- and post-ischemic periods. Each point represents the
mean±SEM of at least 11 animals. *P < 0.05 from control values
using Student's t test for unpaired data.
















ing the pre-ischemic perfusion period. There were no significant
differences in contractility during the ischemic period; however,
the contractility of the transgenic hearts appeared to decline
more slowly compared with the nontransgenic hearts. Although
the temperature of the perfusion apparatus was regulated at
370C, the temperature of the hearts may have decrease slightly
during the ischemic period. However, it is unlikely that such a
decrease in temperature would have contributed to the apparent
difference in contractility during the ischemic period since con-
ditions were similar for the transgenic and nontransgenic hearts.
Significant differences between transgenic and nontransgenic
hearts appeared upon reperfusion. The earliest indication of
protection was at 1 min of reperfusion. The nontransgenic hearts
released a large amount of creatine kinase, indicating cell and
membrane disruption, whereas the transgenic hearts released
almost no creatine kinase (Fig. 6). The contractile force and
±dF/dt recovered stronger in mice overexpressing human
HSP70 (Fig. 5). Almost all hearts in both groups recovered
contractility with 1 min of reperfusion. For both groups, initial
contractile force was strong and then declined at 5 min of reper-
fusion. This decline in contractile force between 1 and 5 min
of reperfusion may be indicative of free radical injury. The
transgenic hearts clearly had better recovery of contractility,
both initially and over the 30-min reperfusion period.
Perfusion pressure, although not significantly different dur-
ing the pre-ischemic perfusion period, appeared to be higher
in nontransgenic than in transgenic mice (Fig. 7). During the
reperfusion period, when flow rate was regulated at 3.0 ml/
min, the transgenic hearts had a significantly lower perfusion
pressure. At present we are uncertain whether the lower perfu-
sion pressure is a result of the transgene product in the cells of
the microvessels. However, it was previously reported that prior
heat shock treatment did tend to lower the perfusion pressure
in isolated rat hearts ( 11). On the other hand, other experiments
suggest that heat shock pretreatment elevated the product of
heart rate multiplied by the mean arterial pressure (rate - pres-
sure product) in rabbits (14).
The presence of human HSP70 in the transgenic hearts
seems to play a role in the improved post-ischemic contractile
recovery. With reperfusion and the introduction of oxygen, oxy-
gen free radicals are generated, and membranes are disrupted
by lipid peroxidation. The release of creatine kinase appears to
be the result of such injury. Although human HSP70 seems to
be involved in reducing this injury, it is unclear whether human
HSP70 is involved directly or indirectly. Studies of human
hsp7O-transfected myocytes have shown increased resistance to
hypoxic or metabolic stresses mimicking ischemia (37, 38).
One possibility is that human HSP70, by its abilities to renature
protein, is modifying the activity of enzymes such as antioxi-
dants, which can protect cells from free radical injury. Although
there is no direct evidence that heat shock proteins can change
the enzymatic activity of antioxidants, catalase activity (11)
and reduced glutathione (39) are reported to be increased after
heat shock treatment. In the present experiments, catalase activ-
ity did not appear to be increased in the transgenic compared
with nontransgenic hearts. However, conclusions about this low
catalase activity should be made cautiously, since these mea-
surements were determined in transgenic and nontransgenic
hearts that were stored at - 80°C for several weeks.
Insights on the role of human HSP70 can be suggested by
analyzing the myocardial contractility during reperfusion. First,
the apparent stronger contractile force recovery at 1 min of
reperfusion suggests that there are more myocytes surviving
after the 30-min ischemic interval. Second, contraction rate
(+dF/dt) and relaxation rate (-dF/dt) of transgenic hearts
progressively increased during reperfusion, whereas the non-
transgenic hearts progressively decreased. This suggests that
reperfusion injury is less in the transgenic hearts. One might
argue that human HSP70 protects myocytes against anoxia-
induced cell death and increases the resistance of myocytes to
oxidative injury. HSP70 may bind to proteins denatured during
ischemia and promote refolding or renaturation to normal con-
figurations upon reperfusion.
These experiments with transgenic mice strongly suggest
that an elevated level of inducible HSP70 plays a role in cell
survival and recovery after ischemic injury. In addition, it seems
that alterations in gene expression, whether induced or engi-
neered (as in this study), can play an important role in the
survival of cells. Understanding the role played by gene expres-
sion and how to regulate such expression after infarction and
other ischemic injuries will lead to new ways of intervening
therapeutically in cardiovascular injury.
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